APDS manifestations are driven by pathogenic gain-of-function variants in PIK3CD (APDS1) or loss-of-function variants in PIK3R1 (APDS2), causing hyperactive phosphoinositide 3-kinase delta signaling (3–9). Here, PIK3CD is linked to activated PI3K-delta syndrome.